Literature DB >> 9204225

Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening.

N Urban1, C Drescher, R Etzioni, C Colby.   

Abstract

The intervention protocol for an ovarian cancer screening trial should be efficient as well as effective, because it may become the standard of care if the trial demonstrates mortality reduction. To identify an efficient ovarian cancer screening protocol, the effectiveness and cost-effectiveness of selected single modality and multimodal screening strategies were estimated using a stochastic simulation model. Screening was simulated over a 30-year period in a hypothetical cohort of 1 million women aged 50 at the beginning of the period. The net present value of the cost per year of life saved was estimated for six protocols involving transvaginal sonography (TVS) and/or the tumor antigen CA 125. Internal and external validation was performed, and sensitivity analyses were conducted to assess the robustness of the ranking of the strategies. A multimodal strategy involving CA 125 with a threshold for positivity of either elevation above 35 U/ml or doubling since the previous screen, followed by TVS only if CA 125 is positive, was found to be efficient in the sense that no other strategies saved as many years of life at lower cost per year of life saved. Used annually, this strategy cost under $100,000 per year of life saved over a range of assumptions. The model's predictions are consistent with results reported in the literature regarding the performance of TVS and CA 125. The multimodal strategy used annually or every six months was efficient compared to either ultrasound or CA 125 used alone, over a range of assumptions. Simulation of screening may be useful in selecting a screening protocol to be tested in a randomized controlled trial.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9204225     DOI: 10.1016/s0197-2456(96)00233-4

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  14 in total

1.  Screening for ovarian cancer. We now need a definitive randomised trial.

Authors:  N Urban
Journal:  BMJ       Date:  1999-11-20

2.  Making decisions about screening for ovarian cancer. Who chooses when an operation is worth having?

Authors:  A Barratt
Journal:  BMJ       Date:  2000-04-01

Review 3.  Selecting a decision model for economic evaluation: a case study and review.

Authors:  J Karnon; J Brown
Journal:  Health Care Manag Sci       Date:  1998-10

4.  Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches.

Authors:  Douglas C A Taylor; Vivek Pawar; Denise T Kruzikas; Kristen E Gilmore; Myrlene Sanon; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

5.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 6.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.

Authors:  Beth Y Karlan; Jason Thorpe; Kate Watabayashi; Charles W Drescher; Melanie Palomares; Mary B Daly; Pam Paley; Paula Hillard; M Robyn Andersen; Garnet Anderson; Ronny Drapkin; Nicole Urban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-01       Impact factor: 4.254

8.  Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer.

Authors:  Lynn M Amon; Wendy Law; Matthew P Fitzgibbon; Jennifer A Gross; Kathy O'Briant; Amelia Peterson; Charles Drescher; Daniel B Martin; Martin McIntosh
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

9.  Indirect estimation of a discrete-state discrete-time model using secondary data analysis of regression data.

Authors:  Deanna J M Isaman; Jacob Barhak; Wen Ye
Journal:  Stat Med       Date:  2009-07-20       Impact factor: 2.373

10.  Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.

Authors:  Maaike Buskermolen; Andrea Gini; Steffie K Naber; Esther Toes-Zoutendijk; Harry J de Koning; Iris Lansdorp-Vogelaar
Journal:  Med Decis Making       Date:  2018-10-20       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.